Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
Date:9/15/2008


WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ --

-- Results inconclusive, as primary outcome measure not statistically

significant for either donepezil or AZD3480; results impacted by

improvement in placebo group

-- Improvements shown on secondary outcome measures ADCS-CGIC and MMSE

-- Overall safety and tolerability profile comparable to placebo, with

fewer GI-related AEs than donepezil

-- Next steps include further analysis of full dataset and planned

discussions with leading medical experts

AstraZeneca (NYSE: AZN) and Targacept, Inc. today announced that results from the Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in mild to moderate Alzheimer's disease were inconclusive.

In the 12-week placebo-controlled study, known as the Sirocco trial, neither the active comparator donepezil nor AZD3480 met the trial's criteria for statistical significance on the primary outcome measure, ADAS-Cog (Alzheimer's Disease Assessment Scale -- Cognition Subscale.) Both results were impacted by an improvement in the placebo group.

At two of the three doses tested, AZD3480 showed an improvement on the secondary outcome measures ADCS-CGIC (Alzheimer's Disease Cooperative Study -- Clinical Global Impression of Change, a 7-point scale), a widely accepted measure of clinician assessment of change in patients' behavior and ability to function, and MMSE (Mini Mental State Examination, a 30-point scale), a quantitative cognition scale commonly used by neurologists in a clinical setting. Of the three AZD3480 doses, the middle dose performed best on both measures (0.5 point improvement, ADCS-CGIC and 0.9 point improvement, MMSE). Donepezil also sh
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
2. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
7. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
8. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
9. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/d8nj6b/europe ) ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... market for Fluoroscopy is expected to grow at a ... is used to view the gastrointestinal tract, to direct ... ducts or the urinary system, to open narrowed or ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. The delivery of drugs to ... the treatment of neurological disorders. Drugs may be ... (e.g., by intravenous injection) for targeted action in ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z9s8mp/laboratory ) has ... - Global Strategic Business Report" report to ... are provided for the period 2014 through 2020. ... these markets. Market data and analytics are derived ... primarily based on public domain information including company ...
Breaking Medicine Technology:European Fluoroscopy Market Report 2014-2019 - Growth, Trends And Forecasts 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2
... TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ ... ingredients (APIs), announced that its,Tainan facility has received ... The Certification confirms ScinoPharm,s,competency and proficiency in the ... applies to specific laboratories and,production areas used for ...
... , CAMBRIDGE, Mass., Nov. 19 Ligon ... to find drugs against high-value targets, today announced that ... incTANK Ventures. The company will use the capital to ... 100 high-value disease protein targets. With this investment, incTANK ...
Cached Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3
(Date:6/2/2015)... Island, N.Y. (PRWEB) June 02, 2015 ... refer to computer generated imagery overlaid on the real ... gone but Vein Visualization, which displays a map of ... shown a steady growth in adoption. , AccuVein, the ... 40% year over year growth rate and such widespread ...
(Date:6/2/2015)... India (PRWEB) June 02, 2015 Bitscape ... in the 2015 Microsoft Worldwide Small and Midsized Cloud ... field of top Microsoft partners for demonstrating excellence in ... technology. , “This comes as no surprise to ... recognized third year consecutively at worldwide level by Microsoft. ...
(Date:6/2/2015)... Washington, DC (PRWEB) June 02, 2015 Did ... you’re wondering what to get him, his family isn’t asking ... Renegades , the team walking in Saturday’s Cure HHT DC ... a genetic disease that causes malformed blood vessels leading to ... began to appear when Ryder was 3 years old ...
(Date:6/2/2015)... On October 1, 2015 the transition to ... , On Monday, June 1st Congressman Kevin ... Ways and Means Committee, and 12 members of the ... Medicaid Services, urging the administration to provide a smooth ... ICD-10 is the newest coding system for healthcare professionals ...
(Date:6/2/2015)... 2015 ANT Wireless, proven innovator in ... of two new products implementing the ANT+ Fitness Equipment ... wireless interoperability in their bike trainer products, built to ... has implemented the FE-C device profile in its Vortex ... its new indoor training software, while Kinomap has added ...
Breaking Medicine News(10 mins):Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:Six-Year-Old Walks to Bring Awareness to Genetic Disease 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3
... the electromagnetic radiation research center feel, that we ... low level radiowaves. Radiowaves and microwaves play an increasing ... computers and personal digital assistants, pagers, and text messengers. ... unaware of their existence. In other words, we are ...
... research shows people with diabetes who are in a ... their unhappily married counterparts. Researchers from the State University ... 70 adults with diabetes who had been married for ... on insulin, were surveyed again two years after the ...
... Atmospheric pollution affects the normal breathing functions. Exposure to ... muscle during exercise in those with heart problems. There ... with both heart disease and lung problems.But a study ... pollution can restrict the oxygen supply to the heart ...
... who eat lots of fruit and vegetables are less ... cent of those with chronic obstructive pulmonary disease (COPD) ... smokers// actually develop COPD - so there must be ... or environmental. ,Researchers at the University of ...
... those who consume wine in moderation have healthier lifestyles overall ... It is well established that moderate alcohol consumption seems ... reduced risk of heart disease. A new study shows that ... factors that produce at least some of the beneficial effects. ...
... the power of a common heart medication in reducing the ... not take the medications. Research shows the use of beta-blocker ... early death by 20 percent. However, many patients fear side ... do not take the drugs. A new study finds there ...
Cached Medicine News:
... The AQT-10 is the ultimate in ... designed to detect the subtle red/green or ... disorders as retinal toxicity (that from Plaquenil, ... retinopathy, and macular degeneration. Additionally it is ...
... Amplifier (UBA-4204) from LKC Technologies, ... amplification and complete electrical isolation ... problems of DC drifting, 50/60Hz ... make the amplifier ideal for ...
... PACHETT 3 uses the exact enhanced corneal ... DGH pachymeters used exclusively by the OHTS ... into the software. The new backlit LCD ... average, standard deviation and IOP correction calculation ...
Orbital Retractor, schepens Retractors, overall length:154mm....
Medicine Products: